News

search close

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

Read more

Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting

Read more

Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

Read more

Relmada Therapeutics Announces Participation in Jefferies Virtual Healthcare Conference

Read more

Relmada Therapeutics Announces Oral Poster Presentation on REL-1017 at 2021 American Society of Clinical Psychopharmacology Annual Meeting

Read more

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

Read more

Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021

Read more

Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021

Read more

Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting

Read more

Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

Read more